levofloxacin has been researched along with sulconazole in 1 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (sulconazole) | Trials (sulconazole) | Recent Studies (post-2010) (sulconazole) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 68 | 11 | 14 |
| Protein | Taxonomy | levofloxacin (IC50) | sulconazole (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.785 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.6 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.704 | |
| Heme oxygenase 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 3.958 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.07 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 2.607 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 4.043 | |
| Adenosine receptor A3 | Homo sapiens (human) | 2.628 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 3.675 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.2 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 6.4 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.628 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.584 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 4.934 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 3.404 | |
| Substance-K receptor | Homo sapiens (human) | 4.958 | |
| Heme oxygenase 2 | Rattus norvegicus (Norway rat) | 1.1 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.027 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.183 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 3.929 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.785 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.141 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.016 | |
| D(3) dopamine receptor | Homo sapiens (human) | 3.104 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.02 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.628 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.726 | |
| Bile acid receptor | Homo sapiens (human) | 6.88 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
1 other study(ies) available for levofloxacin and sulconazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |